Neoplasms: Active vs History of vs Metastatic — Clinical Documentation Guide (2026)

🔍 Definition

A neoplasm is an abnormal proliferation of cells that has escaped normal growth controls, forming a mass (tumor) or disseminated malignant process. Under the ICD-10-CM Official Guidelines for Coding and Reporting (FY2026), neoplasms are classified into four behavioral categories:

• Malignant — invasive, capable of metastasis (C00–C96, C7A, C7B)
• In situ — confined to epithelium without invasion (D00–D09)
• Benign — non-invasive (D10–D36)
• Uncertain/Unspecified behavior — D37–D48 / D49

For clinical documentation and coding purposes, the three status distinctions that drive code selection, sequencing, and HCC risk adjustment are:

• Active malignancy — cancer currently present or under active treatment; assign C-codes (C00–C96).
• History of malignancy — all treatment complete AND no evidence of disease (NED); assign Z85.x personal history codes per ICD-10-CM Guideline I.C.2.d–e.
• Metastatic (secondary) malignancy — primary tumor has spread to secondary sites; code both primary (if active/known) and secondary C77–C79 codes.

This distinction carries enormous financial and clinical documentation stakes: active malignancy codes map to HCC categories with RAF weights of 0.162–1.024+, while Z85.x history codes carry zero HCC weight — a critical teaching point for CDI and coders alike.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Signs and symptoms vary widely by malignancy site and stage. General “constitutional” features common to many cancers include:

• Unintentional weight loss (>10% body weight) — code R63.4 if not integral to neoplasm
• Fatigue, cachexia (C80.1 malignant neoplasm without specified site when cachexia is the focus)
• Night sweats, fever of unknown origin (common in lymphoma/leukemia)
• Pain — neoplasm-related pain G89.3; bone pain M79.3x when metastatic to bone (C79.51)
• Elevated tumor markers: R97.0 (elevated AFP), R97.1 (elevated CEA), R97.20 (elevated PSA), R97.21 (rising PSA post-prostatectomy), R97.8 (other)
• Lymphadenopathy — may indicate nodal metastases (C77.x)
• Pathological fracture — M84.5xxA when secondary to bone metastasis; add C79.51
• Spinal cord compression — G99.2 when due to metastatic disease; add C79.89
• Superior vena cava syndrome — I87.1
• Hypercalcemia of malignancy — E83.52

Site-specific symptoms (hemoptysis in lung cancer, hematuria in bladder cancer, rectal bleeding in colorectal, etc.) should be documented and coded only when they represent a separately addressable condition beyond the neoplasm itself. Per Guideline I.C.2, signs and symptoms integral to the neoplasm are not coded separately.

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

Malignant transformation occurs through a multistep process involving DNA mutations in proto-oncogenes (gain of function) and tumor suppressor genes (loss of function). Key pathophysiologic mechanisms include:

• Initiation: Carcinogen exposure, viral oncogenesis (HPV, EBV, HBV/HCV), or inherited germline mutation alters cell DNA.
• Promotion & progression: Mutated cells gain replicative immortality (telomerase activation), resist apoptosis (BCL-2 overexpression), stimulate angiogenesis (VEGF), and evade immune surveillance (PD-L1 expression).
• Invasion: Loss of cell adhesion (E-cadherin downregulation), matrix metalloproteinase (MMP) secretion digests basement membrane.
• Metastasis (hematogenous/lymphatic): Circulating tumor cells (CTCs) seed distant organs — lung, liver, bone, and brain are the most common metastatic sites for solid tumors. Lymph node involvement is coded C77.x.

ICD-10-CM anatomic code blocks for malignant neoplasms are organized by primary site (per CDC NCHS ICD-10-CM tabular list):

• C00–C14: Lip, oral cavity, pharynx
• C15–C26: Digestive organs (C18 colon, C19 rectosigmoid junction, C20 rectum, C22.0 hepatocellular carcinoma, C22.1 intrahepatic cholangiocarcinoma, C25 pancreas)
• C30–C39: Respiratory system (C34.xx lung — requiring laterality and lobe specificity)
• C40–C41: Bone and articular cartilage
• C43–C44: Skin (C43 melanoma, C44 other malignant skin neoplasms)
• C45: Mesothelioma
• C50.xxx: Breast — requires quadrant (0–9) AND laterality (1 right, 2 left, 9 unspecified)
• C51–C58: Female genital organs (C56.x ovary, C53 cervix, C54 uterus)
• C60–C63: Male genital organs (C61 prostate)
• C64–C68: Urinary tract (C64 kidney, C67 bladder)
• C69–C72: Eye, brain, and CNS (C71.x brain by lobe)
• C73–C75: Thyroid and endocrine glands (C73 thyroid)
• C76–C80: Ill-defined, secondary, and unspecified sites (C80.1 malignant neoplasm without specified site)
• C81–C96: Lymphoid, hematopoietic, and related tissue
• C7A: Malignant carcinoid tumors; C7B: Secondary carcinoid tumors

💊 Medication Impact / Treatment

Pharmacologic treatment of malignancy is highly protocol-driven and directly affects code assignment, sequencing, and encounter management:

• Cytotoxic chemotherapy (alkylating agents, antimetabolites, taxanes, anthracyclines) — coded Z51.11 when the admission’s principal purpose is chemo administration; HCPCS J9xxx for specific agents.
• Immunotherapy / checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab) — coded under chemo admin 96401/96413; document agent for J-code billing.
• Hormone therapy (tamoxifen, aromatase inhibitors, enzalutamide, leuprolide) — document estrogen receptor status Z17.0 (ER+) or Z17.1 (ER–) for breast cancer; documents anti-androgen therapy for prostate.
• Targeted therapy (imatinib, erlotinib, trastuzumab, VEGF inhibitors) — classify under chemotherapy admin codes.
• Corticosteroids (dexamethasone) used as antiemetic/anti-inflammatory during chemo — potential for long-term adverse effects (osteoporosis, adrenal suppression).
• G-CSF/GM-CSF (filgrastim, pegfilgrastim) — used to prevent febrile neutropenia (D70.1); document diagnosis for medical necessity.
• Antiemetics (ondansetron, aprepitant) — manage chemo-induced nausea R11.2.
• Bisphosphonates/RANK-L inhibitors (zoledronic acid, denosumab) — for bone metastases C79.51 and hypercalcemia of malignancy E83.52.
• CAR-T therapy (axicabtagene, tisagenlecleucel) — coded under chemotherapy/infusion admin; document for payer authorization.
• Radiation sensitizers (capecitabine as radiosensitizer in rectal cancer) — dual role, document intent.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, HCC v28 risk adjustment mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides

📘 ICD-10-CM Guidelines (FY2026)

The FY2026 ICD-10-CM Official Guidelines, Section I.C.2 govern all neoplasm coding. Key rules:

I.C.2.b — Treatment Directed at Malignancy

When an encounter is for treatment directly targeting the malignancy (e.g., surgery to excise the tumor), designate the malignancy as the principal diagnosis.

I.C.2.c — Anemia Associated with Malignancy

When the admission/encounter is for management of an anemia associated with malignancy, and the treatment is only for the anemia, sequence the anemia code (D63.0 — Anemia in neoplastic disease) as the principal diagnosis, followed by the malignancy code. Per Guideline I.C.2.c.1.

I.C.2.d — Current Malignancy vs Personal History

• Active: Use active C-code when the neoplasm is still present or the patient is receiving active treatment (including adjuvant chemo/radiation/immunotherapy post-resection).
• History of: Use Z85.x when the malignancy has been excised or eradicated, all treatment is complete, and there is no evidence of recurrence or further treatment.
• Z85.x is NEVER appropriate when any treatment (including adjuvant) is ongoing.

I.C.2.e — Admission for Complication of Malignancy

Sequencing depends on the primary reason for admission:

• Admission for surgery to treat malignancy → malignancy PDx
• Admission for chemotherapy → Z51.11 PDx; malignancy secondary
• Admission for radiation therapy → Z51.0 PDx; malignancy secondary
• Admission for anemia due to malignancy → D63.0 PDx; malignancy secondary
• Admission for dehydration due to malignancy or chemo → E86.0 PDx if dehydration is the primary reason treated
• Admission for surgical site infection complicating prior cancer surgery → T81.4xxA PDx; add malignancy code

Functional Status and Associated Codes

• Z15.01–Z15.09: Genetic susceptibility to malignant neoplasm (BRCA1/BRCA2, Lynch syndrome) — for patients with confirmed genetic predisposition without current malignancy
• Z80.xx: Family history of malignant neoplasm — code for family history screening
• Z17.0 / Z17.1: Estrogen receptor positive / negative status — document for breast/gynecologic cancers
• R97.x: Elevated tumor markers without confirmed malignancy (R97.0 AFP, R97.1 CEA, R97.20 PSA elevated, R97.21 rising PSA post-prostatectomy)
• E34.0: Carcinoid syndrome (functional tumors C7A.x)
• D37–D48: Neoplasms of uncertain behavior — use when pathology cannot confirm malignant vs benign

🔢 ICD-10-CM Code Set (FY2026)

Active Malignancy — Selected Primary Sites

Hematologic Malignancies

Metastatic / Secondary Sites (C77–C79)

Personal History of Malignancy (Z85.x) — Treatment Complete, NED

Supporting / Associated Codes

🔎 Indexing

The ICD-10-CM Alphabetic Index uses the main term “Neoplasm” with a comprehensive Neoplasm Table organized by site. Key indexing rules:

• Look up the anatomic site in the Neoplasm Table under columns: Malignant Primary / Malignant Secondary / Ca in situ / Benign / Uncertain / Unspecified.
• For History of: index under “History, personal (of), malignant neoplasm” → leads to Z85.x codes.
• For metastatic disease when the primary is documented: code both. If the primary is unknown, look up “Neoplasm, unknown primary” → C80.1.
• Histologic type terms (carcinoma, adenocarcinoma, sarcoma, lymphoma) are indexed alphabetically with a cross-reference to the Neoplasm Table.
• Main terms to search: Tumor, Carcinoma, Sarcoma, Lymphoma, Leukemia, Melanoma, Mesothelioma, Myeloma.
• Always verify the tabular list after looking up index — additional notes and excludes1/excludes2 notes apply.

🏥 CPT (2026)

🧾 HCPCS (2026)

📚 AHA Coding Clinic (Recent Guidance)

The following summarizes key guidance from the AHA Coding Clinic for ICD-10-CM/PCS relevant to neoplasm coding:

• Active vs History of: The AHA has consistently reinforced that any ongoing adjuvant therapy — even low-intensity or maintenance-phase therapy — requires the active C-code, not Z85.x. Coders must not independently determine that therapy is “adjuvant” without physician confirmation; query when uncertain.
• Metastatic coding: When the primary site is documented as “resolved” or “resected” and no further primary-site treatment is planned, the primary site may be coded as history of (Z85.x) while the metastatic site carries the active C79.x code — but only when the physician has clearly documented treatment completion at the primary site.
• Lung cancer laterality and lobe: AHA Coding Clinic has directed coders to query for laterality and lobe specificity in lung cancer documentation. “Lung cancer” alone is insufficient; C34.90 (unspecified, unspecified) should be avoided when clinical records permit specificity.
• Breast cancer quadrant and laterality: Documentation of quadrant (upper outer, lower inner, etc.) and laterality (right/left) is required for full code specificity. Pathology reports are an acceptable source for quadrant documentation.
• Lymph node metastases: Coding Clinic has affirmed that when lymph node dissection reveals positive nodes at multiple anatomic regions, code each applicable C77.x code.
• CUP (Cancer of Unknown Primary): Use C80.1 when confirmed metastatic disease exists and the primary site has been thoroughly investigated without identification. Do not use C80.1 simply because primary site workup is pending.
• Neoplasm-related pain (G89.3): May be coded as an additional code to provide specificity, but is not the principal diagnosis unless pain management is the sole reason for encounter.

💰 HCC / Risk Adjustment (v28)

Under the CMS-HCC Model v28 (effective for Medicare Advantage plan year 2026), malignant neoplasms carry some of the highest RAF weights in the entire model. Accurate differentiation between active and history of is the single highest-value coding distinction in cancer documentation:

✍️ CDI Query Templates

All queries below are formatted per AHIMA/ACDIS Guidelines for Query Practice — non-leading, multiple-choice format with clinically relevant options.

🧑‍⚕️ Treatments (Clinical)

Treatment selection depends on histology, stage, molecular markers, and patient performance status. Standard modalities include:

Surgery

• Curative resection: Complete excision with negative margins (R0 resection) — lumpectomy (19301), mastectomy (19303–19307), colectomy (44140–44160), prostatectomy (55840–55866), hepatectomy (47120), pneumonectomy/lobectomy (32480–32484).
• Debulking / cytoreductive surgery: For ovarian cancer (C56.x); reduces tumor burden before platinum-based chemo.
• Lymph node dissection: Sentinel lymph node biopsy (38792–38900 series) or formal lymphadenectomy; results determine nodal staging (C77.x vs negative nodes).
• HIPEC: Hyperthermic intraperitoneal chemotherapy for peritoneal metastases — intraoperative heated chemo perfusion.

Radiation Therapy

• External beam radiation therapy (EBRT) — 3D-CRT, IMRT (77385–77387), SBRT/SABR for oligometastatic disease.
• Brachytherapy (77750–77790) — seed implants for prostate cancer; high-dose-rate (HDR) for gynecologic cancers.
• Stereotactic radiosurgery (SRS) for brain metastases (C79.31) — Gamma Knife, CyberKnife.

Systemic Therapy

• Chemotherapy: Cytotoxic agents administered IV, oral, or intrathecally — protocols include FOLFOX (colorectal), CHOP/R-CHOP (lymphoma), BEP (testicular), AC-T (breast).
• Immunotherapy: Checkpoint inhibitors (pembrolizumab J9271, nivolumab J9299, atezolizumab, durvalumab); CAR-T cell therapy (axicabtagene ciloleucel, tisagenlecleucel).
• Targeted therapy: TKIs (erlotinib, osimertinib for EGFR+ NSCLC; imatinib for CML); HER2-directed (trastuzumab J9355, pertuzumab); PARP inhibitors (olaparib for BRCA+ ovarian/breast).
• Hormone therapy: Aromatase inhibitors (letrozole, anastrozole) and SERMs (tamoxifen) for ER+ breast cancer Z17.0; LHRH agonists (leuprolide J9217) and anti-androgens (enzalutamide) for prostate cancer C61.
• Antiresorptive agents: Zoledronic acid, denosumab for bone metastases (C79.51) and skeletal-related events.

Supportive / Palliative Care

• G-CSF/GM-CSF for chemotherapy-induced neutropenia (D70.1).
• Antiemetics, corticosteroids, and hydration for chemo-induced nausea and dehydration (E86.0).
• Pain management: opioids, adjuvant analgesics, nerve blocks for neoplasm-related pain (G89.3).
• Palliative radiation for pain from bone metastases (C79.51) and brain metastases (C79.31).
• Hospice care when curative intent abandoned — document in records for appropriate Z-code assignment (Z51.5 Encounter for palliative care).

🎓 Patient Education / Summary

For patients and families, the key concepts in cancer diagnosis and coding education include:

Understanding Your Cancer Status

• Active cancer: Your cancer is currently present and/or being treated. Even after surgery, if you are still receiving chemotherapy, radiation, immunotherapy, or hormone therapy, your cancer is considered “active” for medical coding purposes.
• History of cancer: You had cancer in the past, all treatment is complete, and your doctor has confirmed there is no evidence of the cancer returning. Regular surveillance (checkups, labs, imaging) continues, but no active cancer treatment is occurring.
• Metastatic cancer (spread): Your cancer has spread from where it originally started (the primary site) to another part of your body (a secondary site). This is sometimes called “stage IV” or “advanced” cancer.

Why Accurate Documentation Matters

The difference between “active cancer” and “history of cancer” directly affects:

• Insurance coverage and costs: Active cancer codes trigger higher Medicare Advantage risk scores, which help ensure your insurance plan funds the care you need. If your cancer is coded as “history of” when it should be “active,” your plan may receive insufficient funding to cover your care.
• Medical record accuracy: Your complete cancer history helps every provider who treats you understand your background and make safe, informed decisions.
• Treatment eligibility: Certain clinical trials, surgical procedures, and treatments require accurate staging and status documentation.

What Patients Can Do

• Bring your complete medication list to every visit, including all cancer medications, injections, and infusion treatments.
• Clarify with your oncologist whether your cancer is “active” or whether you have completed all treatment.
• Ask for a summary letter after completing cancer treatment documenting that treatment is complete and no evidence of disease exists — this supports accurate coding for future visits.
• Keep records of all imaging results, pathology reports, and treatment summaries.

Key Resources

• National Cancer Institute (cancer.gov) — comprehensive cancer information by type
• American Cancer Society (cancer.org) — patient education, support services
• CDC Cancer Prevention (cdc.gov/cancer) — screening guidelines, statistics
• CMS HCC Risk Adjustment Model — understanding how cancer diagnosis codes affect Medicare Advantage funding

About this Guide

This Clinical Documentation Guide is published by CCO Academy and is intended for credentialed coding, CDI, and clinical documentation professionals. Content is updated for FY2026 ICD-10-CM (effective October 1, 2025). All code assignments should be verified against the official ICD-10-CM Tabular List, AHA Coding Clinic, and applicable payer-specific policies. This guide does not constitute legal, medical, or compliance advice.

Last reviewed: April 2026 · Next scheduled review: October 2026 (FY2027 update)